WorkBoat Header Background Image

WorkBoat+ Membership – Free to Join

The 2026 WorkBoat Diesel Directory is here. See engine specs and manufacturer listings for the U.S. commercial fleet. → Download Free

Workboat Indexes

Recent Quotes
My Watchlist
Indicators
Local Stocks
Markets
Workboat Indexes
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Allogene Therapeutics, Inc.

< Previous 1 2 3 4 Next >
News headline image
Allogene Therapeutics Presents Updated ALLO-501/501A Phase 1 Data in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Participation in Three Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Encore Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the European Hematology Association (EHA) Hybrid Congress
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Reports First Quarter 2023 Financial Results and Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Presentation of Phase 1 Data from the ALLO-501/501A Trials in Large B Cell Lymphoma at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics to Report First Quarter 2023 Financial Results on May 3, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Appoints Timothy Moore as Chief Technical Officer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Presents Interim Phase 1 Data on ALLO-316 in Renal Cell Carcinoma at the American Association of Cancer Research (AACR) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Participation in Four Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Publishes 2022 Annual Environmental, Social and Governance (ESG) Report
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Oral Presentation of Phase 1 Data on ALLO-316 at the American Association of Cancer Research (AACR) Annual Meeting
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Publication of Industry-Advancing Case Study on Chromosomal Rearrangement in Molecular Therapy
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics to Report Fourth Quarter and Year-End 2022 Financial Results on February 28, 2023
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform Technology
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Publishes Preclinical Data in Clinical Cancer Research Supporting DLL3 as a Potential AlloCAR T™ Target for Small Cell Lung Cancer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple Myeloma
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Participation in Two Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Appoints Zachary J. Roberts, M.D., Ph.D. as Executive Vice President of Research & Development
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics R&D Showcase Features Hematologic and Solid Tumor Advances Across its AlloCAR T™ Platform
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Unveils Novel Approach to Generate Engineered AlloCAR T™ Cells to Control Immune Rejection at the Annual Meeting of the Society for Immunotherapy of Cancer
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics To Host Research & Development Showcase and Participate in Five Upcoming Investor Conferences
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of Hematology
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D Showcase
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in Asia
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Launches CAR T Together™, a First-of-its-Kind Initiative with Leading Oncologists Nationwide, Focused on Accelerating Development and Clinical Trial Recruitment for “Off-The-Shelf” Allogeneic Cell Therapy Investigational Products
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
News headline image
Allogene Therapeutics Initiates Industry’s First Allogeneic CAR T Phase 2 Trial
From Allogene Therapeutics, Inc.
Via GlobeNewswire
Tickers ALLO
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Privacy Policy DSAR Requests Terms of Use Locations Events, Products & Services
© 2026 Diversified Communications. All rights reserved.